Sign in

What researchers published on Thalassaemia

7,352 papers, newest first.

Showing 20 of 281

  • Randomised trialAdjunctive Resveratrol or Omeprazole in Patients with Non-Transfusion-Dependent Thalassemia with Iron Overload: A Randomized, Double-Blind, Placebo-Controlled Trial.International journal of molecular sciences
  • Randomised trialEfficacy and safety of mitapivat in adults with transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.Lancet (London, England)
  • Randomised trialDulaglutide vs insulin in adolescents with thalassaemia-induced diabetes: effect on metabolism and atherogenesis (DIADEMA).Diabetologia
  • Randomised trialEffectiveness of Genetic Counseling Modalities on Knowledge, Attitudes, and Premarital Screening Intentions for Thalassemia Prevention: A Multi-Site Three-Arm Randomized Controlled Trial.International journal of environmental research and public health
  • Trial resultFludarabine, Busulfan, Thiotepa, and Melphalan: A Novel Low-Toxicity Myeloablative Conditioning Regimen for Haploidentical HSCT in Children and Adolescents Aged ≥7 Years With Transfusion-Dependent β-Thalassemia.Pediatric blood & cancer
  • Trial resultChronic Red Cell Exchange for the Management of Alpha Thalassemia Major Complicated by Iron Overload.Journal of clinical apheresis
  • Trial resultExa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease.The New England journal of medicine
  • Trial resultCorrection of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion-Dependent β-Thalassemia.American journal of hematology
  • Randomised trialThe effect of psychoeducation program on hope, stress coping, and psychiatric symptoms in patients with Thalassemia major.Archives of psychiatric nursing
  • Trial resultIn utero hematopoietic cell transplantation in fetuses with α-thalassemia major: a phase 1 clinical trial.Blood advances
  • Trial resultClinical application of base editing for treating β-thalassaemia.Nature
  • Trial resultCRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia.The New England journal of medicine
  • Randomised trialPatient-Reported Outcomes With Luspatercept Through 5 Years of Treatment in Patients With Non-Transfusion-Dependent β-Thalassemia Treated in the BEYOND Trial.European journal of haematology
  • Trial resultSafety and efficacy of hemobeglogene autotemcel(hemo-cel) gene therapy in five patients with transfusion-dependent β-thalassemia.Molecular therapy : the journal of the American Society of Gene Therapy
  • Trial resultLong-term efficacy and safety results of betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemia.Blood
  • Randomised trialRandomized double-blind crossover trial of a transdermal maltose dissolvable microneedle patch for topical anesthesia before intravenous cannulation for thalassemia children.Scientific reports
  • Randomised trialSafety and pharmacodynamics of the ferroportin inhibitor vamifeport in patients with non-transfusion-dependent β-thalassemia: results from a randomized phase 2a study.Orphanet journal of rare diseases
  • Trial resultScreening, genetic analysis, and clinical transfusion implications of thalassaemia and glucose-6-phosphate dehydrogenase deficiency in blood donors.Transfusion medicine (Oxford, England)
  • Randomised trialAchieving clinically meaningful changes in haemoglobin levels in patients with non-transfusion-dependent β-thalassaemia treated with luspatercept: A post hoc analysis of the phase 2 BEYOND trial.British journal of haematology
  • Randomised trialCorrelation of plasma lipidomic profiles with cardiometabolic disease in transfusion-dependent thalassemia patients with six-month N-acetylcysteine intervention: A prospective cohort study.Clinical biochemistry